Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites by Ekala, Marie-Thérèse et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Malaria Journal
Open Access Research
Sequence analysis of Plasmodium falciparum cytochrome b in 
multiple geographic sites
Marie-Thérèse Ekala1, Nimol Khim2, Eric Legrand3, 
Milijaona Randrianarivelojosia4, Ronan Jambou5, Thierry Fandeur1,2, 
Didier Menard4, Serge-Brice Assi6, Marie-Claire Henry6, Christophe Rogier7, 
Christiane Bouchier8 and Odile Mercereau-Puijalon*1
Address: 1Immunologie Moléculaire des Parasites, CNRS URA 2581, Institut Pasteur, 25 rue du Dr ROUX, 75724 Paris Cedex 15, Paris, France, 
2Unité d'Epidémiologie Moléculaire, Institut Pasteur du Cambodge, Phnom Penh, Cambodia, 3Laboratoire CNRCP Cayenne, Institut Pasteur de 
la Guyane, French Guiana, 4Unité de Recherche sur le Paludisme, Institut Pasteur de Madagascar, Antananarivo, Madagascar, 5Laboratoire 
d'Immunologie Parasitaire, Institut Pasteur de Dakar, Dakar, Senegal, 6Institut Pierre Richet, Bouaké, Ivory Coast, 7Institut de Médecine Tropicale 
du Service de Santé des Armées, Marseille, France and 8Plate-forme Génomique – Pasteur Génopole Ile de France, Institut Pasteur, Paris, France
Email: Marie-Thérèse Ekala - mtekala@yahoo.com; Nimol Khim - knimol@pasteur-kh.org; Eric Legrand - elegrand@pasteur-cayenne.fr; 
Milijaona Randrianarivelojosia - milijaona@pasteur.mg; Ronan Jambou - rjambou@med.usyd.edu.au; Thierry Fandeur - tfandeur@pasteur.fr; 
Didier Menard - dmenard@pasteur.mg; Serge-Brice Assi - assisergi@yahoo.fr; Marie-Claire Henry - marie-claire.henry@ird.fr; 
Christophe Rogier - christophe.rogier@wanadoo.fr; Christiane Bouchier - bouchier@pasteur.fr; Odile Mercereau-Puijalon* - omp@pasteur.fr
* Corresponding author    
Abstract
Background:  The antimalarial drug atovaquone specifically targets Plasmodium falciparum
cytochrome b (Pfcytb), a mitochondrial gene with uniparental inheritance. Cases of resistance to
atovaquone associated with mutant Pfcytb have been reported, justifying efforts to better document
the natural polymorphism of this gene. To this end, a large molecular survey was conducted in
several malaria endemic areas where atovaquone was not yet in regular use.
Methods: The polymorphism of the Pfcytb was analysed by direct sequencing of PCR products
corresponding to the full length coding region. Sequence was generated for 671 isolates originating
from three continents: Africa (Senegal, Ivory Coast, Central African Republic and Madagascar), Asia
(Cambodia) and South America (French Guiana).
Results: Overall, 11 polymorphic sites were observed, of which eight were novel mutations. There
was a large disparity in the geographic distribution of the mutants. All isolates from Senegal, Central
African Republic and Madagascar displayed a Camp/3D7 wild type Pfcytb sequence, as did most
samples originating from Cambodia and Ivory Coast. One synonymous (t759a at codon V253V) and
two non-synonymous (t553g and a581g at codons F185V and H194R, respectively) singletons were
detected in Ivory Coast. Likewise, two synonymous (a126t and c793t at codons -T42T and L265L,
respectively) singletons were observed in Cambodia. In contrast, seven mutated sites, affecting
seven codons and defining four mutant haplotypes were observed in French Guiana. The wild type
allele was observed in only 14% of the French Guiana isolates. The synonymous c688t mutation at
position L230L was highly prevalent; the most frequent allele was the c688t single mutant, observed
in 84% of the isolates. The other alleles were singletons (a126t/a165c, a4g/a20t/a1024c and a20t/
t341c/c688t corresponding to T42T/S55S, N2D/N71I/I342L, N71I/L114S/L230L, respectively"
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please replace with ' corresponding to T42T/S55S, N2D/N71I/I342L and N71I/L114S/L230L,
respectively). The codon 268 polymorphisms associated with atovaquone resistance were not
observed in the panel the isolates studied. Overall, the wild type PfCYTb protein isoform was highly
predominant in all study areas, including French Guiana, suggesting stringent functional constraints.
Conclusion: These data along with previously identified Pfcytb field polymorphisms indicate a
clustering of molecular signatures, suggesting different ancestral types in South America and other
continents. The absence of mutations associated with most atovaquone-proguanil clinical failures
indicates that the atovaquone-proguanil association is an interesting treatment option in the study
areas.
Background
A high rate of treatment failure for commonly anti-malar-
ial drugs used in Plasmodium falciparum infections has
been reported in numerous endemic areas. The recom-
mended treatment policy is now to use drug combina-
tions [1]. The atovaquone-proguanil (AP) drug
combination, distributed under the trade name of Malar-
one®, is one of the treatment and prophylaxis options. AP
has a high cure rate, limited mild side effects [2] and
proved efficacious against multi-drug resistant P. falci-
parum malaria [3,4]. Atovaquone (a hydroxy-naphthoqui-
none) is a potent inhibitor of the cytochrome bc1
(cytbc1) complex [5-8], a key respiratory enzyme from the
mitochondrial membrane, while proguanil (an isopropyl-
biguanide) inhibits the plasmodial dihydrofolate reduct-
ase [4,9,10]. The association synergizes to collapse the
mitochondrial membrane [8,11].
Plasmodium falciparum in vitro resistance to atovaquone
has been associated with specific point mutations in the
cytochrome b gene (Pfcytb) in the region spanning codons
271–284 [7,12]. A high frequency of recrudescence was
observed in patients receiving atovaquone as a single drug
therapy against P. falciparum [13,14]. A Y268S point
mutation in the Pfcytb gene, distinct from the mutations
observed in the lines selected in vitro for atovaquone
resistance, was detected in the recrudescing parasites [7].
Codon 268 polymorphism was used as marker for a
molecular surveillance of atovaquone-proguanil resist-
ance [15-19]. AP treatment failures were increasingly
reported a few years after its introduction, with recrudesc-
ing parasites presenting a markedly increased IC50 for
atovaquone [15,20,21]. In most cases, recrudescence was
associated with a mutant 268 codon, either a Y268S
[3,12,20,22-26], a Y268N [15] or a Y268C mutation [21].
However, the presence of a mutant 268 codon was not
observed in all cases of AP failure [21,27].
Along with the key issue of emergence and spreading of
polymorphisms conferring atovaquone resistance, analy-
sis of Pfcytb field diversity presents an interest in popula-
tion genetics [28-31]. Indeed, the cytb gene is encoded by
the mitochondrial DNA and as a consequence, is of uni-
parental inheritance and under quite different evolution
constraints compared to nuclear genes [32,33]. In particu-
lar, interallelic recombination is not possible and poly-
morphisms such as base substitutions or insertions may
accumulate over time. In mammals, the cytb locus displays
an approximately 10-fold higher mutation rate than
nuclear genes [34]. A rapid mutation rate (one mutation
in 105  parasites) was reported for Pfcytb  [35], but
100–1,000 lower rates were described subsequently [7].
Sequence polymorphism of the near to full gene sequence
has been explored in laboratory [7,36] and in vitro resist-
ant isolates [7,12]. It has also been looked for in cases of
treatment failures from several countries, mostly African
countries [7,12,15,21,22,24-26]. Systematic analysis of
field polymorphism in African settings [37,38] and in iso-
lates from the Thai Myanmar border [39] essentially
focused on the region coding for the atovaquone-binding
site. Full gene sequence analysis of field samples has been
restricted to isolates from few patients in India [36] and
from patients returning to France from West Africa, Cen-
tral Africa or the Indian Ocean [21,25,40]. This provides
an interesting picture of the overall polymorphism of the
gene, but little clues on possible population signatures
related to this gene. Sequence analysis of mitochondrial
DNA from 100 independent isolates   collected worlwide
provided evidence for geographical clustering [29,30].
To further document Pfcytb  population polymorphism,
671 isolates from six different areas: Africa (Senegal, Ivory
Coast, Central African Republic, and Madagascar), Asia
(Cambodia) and South America (French Guiana) were AP
had not been in regular use were analysed. This identified
numerous novel, low frequency polymorphisms in Africa
and Cambodia, most of which were country-specific,
together with a high frequency signature that was specific
for the South American isolates. None of the polymor-
phisms previously associated with atovaquone resistance
in vitro or AP treatment failure was observed in this panel
of isolates.Malaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
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Methods
Study-sites and sample collection
Isolates were collected during the drug susceptibility sur-
veillance programme conducted by the reference labora-
tory based in French Guiana, as such they were exempt
from consent. Additional isolates originating from Sen-
egal [41], Madagascar, Cambodia [42], Ivory Coast [43]
and Central African Republic [44] were collected from
patients recruited at home or at health centres during reg-
ular control surveys. Informed consent was obtained for
these studies.
Blood samples were collected in each country from
patients with mild malaria in the years 2000–2003, except
in Central African Republic where blood was collected in
the year 2004. After blood smear analysis, patients with
mixed species infections were excluded. Only patients
with positive slides for P. falciparum were included (Sen-
egal : Sn, N = 45 ; Madagascar : Mg, N = 192 ; Ivory Coast
: IC, N = 44 ; Cambodia : Kh, N = 179 ; French Guiana :
FG, N = 160 ; Central African Republic : RCA, N = 51).
Blood was stored frozen before being processed for
genomic DNA isolation and amplification.
DNA extraction and Polymerase Chain Reaction (PCR) 
amplification
Parasite DNA was extracted from frozen blood aliquots
using the phenol/chloroform method [45]. Amplifica-
tions were performed in 50 μL final reaction volume con-
taining DNA template, 1 μM each primer, 200 μM each
dNTP, 1.75 mM MgCl2 and 2.5 U Taq polymerase
(Promega) using a Mastercycler Gradient 5331, Eppen-
dorf. The primers were designed to amplify the full length
Pfcytb gene, using as reference sequence the atovaquone-
sensitive  P. falciparum 3D7 clone (accession No
AY282930), and carried an extension sequence (bold)
that was used as sequencing primer as well: cytb1-sense
(ctcgaggaattcggatcctatgaacttttactctattaatt) and cytb2-anti-
sense (tctagaaagcttggatcctatatgtttgcttgggagct). The PCR
amplification conditions were: 1 cycle denaturation at
94°C for 3 min, followed by 5 cycles [94°C for 30 sec,
56°C for 90 sec, 65°C for 150 sec] and 35 cycles [94°C for
10 sec, 53°C for 90 sec, 65°C for 150 sec]. A final exten-
sion was done at 65°C during 15 min. The isolates from
Ivory Coast were amplified using the primers CYTb1 and
CYTb2 [12].
Direct sequencing of PCR products
The PCR products were purified using a P-100 Gel Fine
solution (Bio-Rad) and Multiscreen MAVN45 kit system
(Millipore). The amount of PCR product (1131 bp) was
estimated on a 1.2% agarose gel. Sequencing reactions
were performed on both strands using the extension prim-
ers (sequence in bold indicated above) and internal prim-
ers using ABI Prism BigDye Terminator chemistry.
Sequencing reactions conditions were as follows: 1 cycle
at 96°C for 60 sec, followed by 25 cycles [96°C for 10 sec,
50°C for 5 sec, 60°C for 4 min]. The product was ethanol
precipitated and washed with 70% Ethanol. The pellets
were resuspended in 10 μL 0.3 mM EDTA and sequenced
using an ABI PRISM 3100 Genetic analyzer (Applied Bio-
systems).
The isolates from Ivory Coast were sequenced on both
strands with the internal primers PfCYTB33 (5'atttatga-
tatttattgtaactgc) and PfCYTB4R (5'agttggttaaacttctttgt-
tctgc), covering codons 122 to 294 (i.e. encompassing the
binding site of atovaquone).
Data analysis
Sequence analysis was done using Phred Phrap consed
package [46]. Sequences with segments ≥ 1000 bp called
with a quality over 20 per base were retained. Only unam-
biguous single nucleotide polymorphisms (SNPs) were
considered. Sequences of insufficient quality were either
resequenced or rejected. The sequence assembly was done
with the Seqscape software v.2.0. (Applied Biosystems).
Results
Among the 671 isolates, a full length Pfcytb sequence was
successfully established for 576 isolates and partial
sequence was obtained for 95 isolates (Figure 1). Overall,
11 polymorphic sites were observed (Figure 1), of which
eight were novel mutations compared with published
data (Figure 2).
All isolates from Senegal, Central African Republic and
Madagascar had the same sequence, which was identical
to the Camp/3D7 reference sequence. One synonymous
point mutation and two coding mutations were observed
in the set of isolates from Ivory Coast (Figure 1). None of
these had been published previously and each was
observed in a single isolate.
In Cambodia, two synonymous mutations (T42T and
L265L) were observed (Figure 1). Each was detected in
one isolate, the remaining 177 isolates harboured the
Camp/3D7 reference Pfcytb gene sequence.
The French Guiana samples presented the largest poly-
morphism, with seven mutated sites affecting seven
codons. Five alleles were observed (Figure 1). Unlike the
other settings where alleles had a single mutated position,
three out of the five alleles from French Guiana were mul-
tiple mutants with two (allele FG2) or three (alleles FG3
and FG4) mutated codons. The Camp/3D7 reference
allele was present in 22 out of 160 isolates (14%). Allele
FG1, which carried a silent L230L mutation, was highly
predominant, accounting for 135 of 160 (84%) isolates
(Figures 1 and 3). The same mutation was associated withMalaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
Page 4 of 9
(page number not for citation purposes)
additional SNPs in allele FG4, which therefore probably
derive from FG1. Allele FG4 which carried additional
mutations N7I and L114S, was observed only once (fre-
quency 0.6%). The N7I polymorphism was detected in
allele FG3 as well, but in this case it was associated with
N2D and I342L (Figure 1).
Discussion
In the panel of isolates studied here, 11 polymorphic sites
were observed, resulting in 11 codons displaying a single
point mutation. Ten distinct alleles could be identified, as
shown in Figure 1. Apart from the a126t and c688t silent
mutations at codon T42T and L230L, respectively, and
a581g non synonymous mutation at codon H194R, all
mutations observed here were novel (Figures 1 and 2).
Five synonymous and six non-synonymous mutations
were detected. The observed ratio of synonymous to non
synonymous mutations is in line with four synonymous
and five non synonymous mutations detected in 270 full
gene sequences of isolates from West Africa and the
Indian Ocean [25] and four synonymous and six non syn-
onymous mutations in 14 isolates from India [36], but
lower than the three to one ratio observed in Gabon [37]
and the nine to three ratio reported for 135 isolates from
West and Central Africa [40]. The compilation of all Pfcytb
field polymorphisms identified so far (Figure 2) high-
lights 50 polymorphic sites, affecting 45 codons, with 30
mutant amino acid residues.
There was a clear geographical heterogeneity in the level
and type of polymorphism (Figure 3). The Camp/3D7
type was the single allelic form detected in three African
settings studied here (Madagascar, Senegal and Central
African Republic). Similar observations were made in
Ethiopia [37]. In Ivory Coast, the same allele was observed
in 93% of the patients, a frequency similar to the 90%
prevalence observed in Gabon [37], or in travellers return-
ing to France from West and Central Africa [40]. As
observed in other African endemic settings [37], the
mutant alleles were single mutants and each mutant had
a low frequency, being observed in one or two isolates. A
similar low frequency of single mutant alleles has been
observed in the panel of isolates from patients returning
from travel to West and Central Africa and the Indian
Ocean [25,40].
In Cambodia, the Camp/3D7 wild type allele was also
highly predominant, consistent with recent sequence data
of the atovaquone binding site in patients from the Thai/
Myanmar border [39]. The two mutations observed were
both synonymous and detected at low frequency.
Individual Pfcytb polymorphisms and allelic types observed in the study areas Figure 1
Individual Pfcytb polymorphisms and allelic types observed in the study areas. WT : wild type ; * non synonymous 
mutation; ° synonymous mutation. The polymorphic sites observed in this study are shown by codon (numbers refer to posi-
tions in the protein sequence). Amino acids are indicated with single letter code and in capital, the nucleotide changes are indi-
cated below (bold). Area-specific mutations are coloured in brown, blue and orange for Ivory Coast, Cambodia and French 
Guiana, respectively. In grey, T42T, the only mutation found common between two settings.
N2D* N7I* T42T° S55S° L114S* F185V* H194R* L230L° V253V° L265L° I342L*
AAC>GAC AAT>ATT ACA>ACT TCA>TCC TTA>TCA TTT>GTT CAT>CGTC T A > TTA GTT>GTA CTA>TTA ATT>CTT
Senegal WT (n=45)
(n=45)
Madagascar WT (n=192)
(n=192)
IC1 (n=1)
Ivory Coast IC2 (n=1)
(n=44) IC3 (n=1)
WT (n=41)
Central Africa WT (n=51)
(n=51)
Kh1 (n=1)
Cambodia Kh2 (n=1)
(n=179) WT (n=177)
FG1 (n=135)
FG2 (n=1)
French Guiana FG3 (n=1)
(n=160) FG4 (n=1)
WT (n=22)Malaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
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French Guiana showed a quite different profile, and was
the most polymorphic of the six countries explored. Seven
of 11 mutant sites were observed in the set of isolates from
French Guiana. Furthermore, this area was the only one
where multiple mutant alleles were detected. Importantly,
the Camp/3D7 wild type allele, which was dominant in
the other settings was observed with a 14% frequency
only, while the dominant allele (84% frequency) was a
single, silent L230L mutant. This was in accordance with
data from other localities from South America [29,30].
Triple mutants, most probably originating from the L230L
parent for FG4 isolate, were observed along with a double
mutant possibly derived from the Camp/3D7 type. Thus,
the French Guiana parasite population had a Pfcytb pat-
tern dissimilar from the African and Cambodian settings.
This was consistent with data from others [29,30]. A spe-
cific, high frequency geographical signature seems to pre-
vail in India as well, where 13 or 14 isolates carried a N2N
F3Y Y4Y haplotype [36]. However, polymorphism in
French Guiana was larger than in India, where three allelic
forms have been reported. Thus, of all geographical areas
studied so far, French Guiana presents the largest Pfcytb
gene polymorphism. This is interpreted as a consequence
of its population structure, with hypoendemic, isolated
foci that are propitious to genetic drift [47].
Compilation of the polymorphic sites of the Pfcytb gene in field isolates (in blue) and in lines selected for atovaquone-resistance  in vitro (in yellow) Figure 2
Compilation of the polymorphic sites of the Pfcytb gene in field isolates (in blue) and in lines selected for 
atovaquone-resistance in vitro (in yellow). The figure does not include silent mutations, which were not described [36] 
or whose nucleotide numbering does not match with the reported reference sequences [37, 40]. Numbering indicated refers 
to data reported from 1-Korzinczky et al [7]; 2-Schwöbel et al. [12]; 3-Sharma et al. [36]; 4-Musset et al. [25]; 5-Fivelman et al. 
[15]; 6-Berry et al. [40]; 7-Happi et al. [38]; 8-Kuhn et al. [24]; 9-Färnert et al. [23]; 10-David et al. [22]; 11-Schwartz et al. [26]; 
12-Musset et al. [21]; 13-Joy et al. [30]; 14-Conway et al. [29]; 15-Legrand et al. [20]. # Single Nucleotide Polymorphism found 
in this study; * Musset personal communication; ** codon 282 is GTA : nucleotide 846 is an A and not a C as quoted by Berry 
et al [40], we assume that the T to C mutation affects nucleotide 845
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SNP nucleotide AA residue
a4g N2D #
c6t N2N 3
t8a F3Y 3
c12t Y4Y 3
a20t N7I #
t22c L8L 13
c63t N21N 13
c90t F30F 4*
a126t T42T ## 4 *
g160c V54L
a165t S55S #
g209a S70N 4
c234t H78H 13 4*
t273c L91L 3
a275g H92R 3
t341c L114S #
t363c T121T 13
c369a F123L 15
g370a  t372g V124M 15
a377t Y126F 3
g399a  M133I  12
a471t  G157G  13
c494g  T165R  3
t553g F185V #
a581g H194R #, *
c688t L230L # 13,14 *
g757a V253I 6
t759a V253V #
c793t L265L #
c796a P266T 7
t802a Y268N 5,7
a803c Y268S 15 1 4 8 4 9,4 4 10 11
a803g Y268C 12 12
a813c  L271F  2
a815g K272R 1
c823a P275T 1
g839a G280D 1
t845c** V282A 6
t849a L283I 1
g850a  t851a V284K 1
a861t S287S 3
t862a L288I 3
g896a S299N 12
t918a F306L 4
t929a F310Y 3
t977c F326S 3
a1024c I342L #
c1059t F353F 4*
c1086t H362Q 4
South America In vitro Africa AsiaMalaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
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Pfcytb  nucleotide polymorphism was larger than the
deduced protein sequence. All three alleles from Cambo-
dia coded for the same, wild type protein sequence. In
French Guiana the wild type deduced protein sequence
accounted for 158 of 160 alleles. Thus in all geographic
regions, the wild type protein sequence was the highly
dominant if not the only predicted isoform. Altogether,
these data point to an elevated mutation rate of the locus,
with albeit a large dominance of the wild type protein
sequence, probably indicating its optimal fitness. At the
nucleotide level, interesting geographic clustering of
molecular signatures were observed (Figure 4), suggesting
different ancestral types in French Guiana (and in South
America) as well as in India [36]. Specificities of the para-
site population in India is also suggested by polymor-
phism of the Pfcrt  locus [48]. The data reported here
further support the evidence that the present parasite pop-
ulation from South America differs from the parasites
from Africa, regarding surface antigens [49], loci such as
Pfcg2  [31],  Pfcrt  [50-52],  Pfdhfr  and  Pfdhps  [51] and
numerous genome-wide scattered SNPs [53]. The large
Pfcytb polymorphism together with the observation that
the var gene repertoire in Brazilian isolates is small and
highly redundant unlike in Africa and Southeast Asia [54],
raises the question of the structuring of the South Ameri-
can P. falciparum population.
None of the field polymorphism observed here or in other
settings concerned the residues that are mutated in lines
selected in vitro for atovaquone resistance [5,7,12]. Fur-
thermore, no mutant Y268S, Y268C and Y268N Pfcytb,
selected under atovaquone or AP pressure
[3,7,12,15,21,22,24-26] was detected in any of the set-
tings explored here. The 268N mutant, which has been
observed with a 4.5% frequency in Nigeria in the absence
of AP pressure [38] was not detected. This mutation has
been reported so far essentially in Nigeria [15,38] and, as
discussed by Happi et al [38] may have arisen under pres-
sure by related drugs. The Y268S polymorphism was not
detected in the isolates from French Guiana studied here,
which were collected before implementation of AP as
prophylaxis and as second line treatment in 2002. It was
however observed one year after implementation in a sec-
Geographic distribution of the Pfcytb gene polymorphism studied here Figure 3
Geographic distribution of the Pfcytb gene polymorphism studied here. Country's code: FG: French Guiana, Sn: Sen-
egal, IC: Ivory Coast, RCA: Central Africa, Mg: Madagascar, Kh: Cambodia. Allelic frequency in each site is depicted in colour 
coded pie charts: brown, blue and orange referring to Ivory Coast, Cambodia and French Guiana, respectively. The wild type 
allele (WT) is indicated in white.
L230L (> 84%)
WT WT
(0 SNP)
WT
(0 SNP)
WT
(0 SNP)
WT
WT
IC IC
FG FG
Kh Kh
Mg Mg
RCA RCA
WT
Sn SnMalaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
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Phylogenetic relationship among 20 Pfcytb alleles from various geographical origin Figure 4
Phylogenetic relationship among 20 Pfcytb alleles from various geographical origin. The tree was estimated using 
the Phylip DNAdist program and the neighbour-joining method (100 replications), and drawn using Drawtree software. Among 
the various Pfcytb haplotypes previously published, only those corresponding to a natural polymorphism of the gene (i.e. not 
selected under atovaquone pressure) were considered for the phylogenetic analysis. The 3D7 sequence 
>gi|31789515|gb|AY282930 was used as reference. The haplotypes were as follows: Nga1: G757A [40]; Nga2: T802A, Nga3: 
C796A [38]; Sen1: G160C, Sen2: G209A, Mali1: T918A, Mali2: T1086A, Ben1: A126T, Com: C234T, Burk1: C1059T, RCA1: 
C90T [21]; Kh1: A126T, Kh2: C793T, FG1: C688T, FG2:A126T/A165C, FG3:A4G/A20T/A1024C; FG4:A20T/T341C/C688T 
(this paper); Ind1: T273C/A377T/C494G/A861T/T862A/T929A, Ind2: C6T/T8A/C12T/A275G, Ind3: C6T/T8A/C12T/A275G/
T977C [36]. Codes used for countries: Senegal: Sen, Comoro islands: Com, India: Ind, Central Africa: RCA, Mali, Nigeria: Nga, 
French Guiana: FG, Benin: Ben, Burkina Faso: Burk, Kh: Cambodia.
Mali1
FG4
FG1
FG3
Sen2
Burk1
Ind1
3D7
Nga1
Mali2
Sen1 Nga2
Ben1 Kh1
FG2
Kh2
RCA1
Nga3
Ind3
Ind2
Com1Malaria Journal 2007, 6:164 http://www.malariajournal.com/content/6/1/164
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ond line AP-treatment failure [20], further substantiating
the interpretation of its selection during AP treatment.
Conclusion
Overall, the available data indicate an elevated mutation
frequency of the Pfcytb locus, with multiple polymorphic
sites, and in some cases more than one polymorphism per
site, consistent with the elevated mutation frequency of
mitochondrial genes [34,35]. The geographical clustering
observed here adds further support to the evidence that
the parasite population from South America differs from
the parasites from Africa. Importantly, the absence of a
mutated codon 268 in all settings investigated here indi-
cates that AP remains an interesting treatment option for
these areas. In view of the high mutation rate and of the
rapid selection of mutants under AP pressure, careful sur-
veillance of emerging Pfcytb  mutants and resistance to
atovaquone used as prophylaxis in travellers or as treat-
ment is warranted.
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